Track the Kiniksa Pharmaceuticals, Ltd. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Operating in the Health Care sector, Kiniksa Pharmaceuticals, Ltd. has published 83 reports. Market capitalisation: €4.2bn. The latest transaction was disclosed on 7 June 2024 (Levée d'options). Among the most active insiders: Megna Michael R. The full history is openly available.
83
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€1m
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Kiniksa Pharmaceuticals, Ltd. Strong Buy (bullish), based on 8 analysts. Average price target: US$63.50.
41Σ signal
Buys ·€1m Sells
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 11,144 of 25,514 companies
55.1
score / 100
Value
34
Quality
77
FCF yld3.4%
Earn yld1.5%
EV/EBITDA50.8x
ROE14%
Gross mgn55%
Net mgn8.7%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.